Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,036.52 USD
+9.97 (0.97%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $1,043.70 +7.18 (0.69%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
REGN 1,036.52 +9.97(0.97%)
Will REGN be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for REGN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for REGN
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
Top Stock Reports for Procter & Gamble, ServiceNow & Lockheed Martin
REGN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
Health Care Stocks Show Relative Strength as S&P 500 Stalls
Other News for REGN
Sanofi's Immunology Business Is Doing A Lot Of Heavy Lifting
Regeneron presents follow-up data from pivotal Phase 1/2 LINKER-MM1 trial
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
Ocular Therapeutix jumps after investor day updates
Regeneron wins injunction blocking Samsung Bioepis from launching generic Eylea